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Abstract
Background: Rare mutations of the epithelial sodium channel (ENaC) result in the monogenic
hypertension form of Liddle's syndrome. We decided to screen for common variants in the ENaC
βand γ subunits in patients with essential hypertension and to relate their occurrence to the activity
of circulating renin-angiotensin-aldosterone system.
Methods: Initially, DNA samples from 27 patients with low renin/low aldosterone hypertension
were examined. The DNA variants were subsequently screened for in 347 patients with treatment-
resistant hypertension, 175 male subjects with documented long-lasting normotension and 301
healthy   Plasma renin and aldosterone levels were measured under baseline conditions and during
postural and captopril challenge tests.
Results: Two commonly occurring βENaC variants (G589S and a novel intronic i12-17CT
substitution) and one novel γENaC variant (V546I) were detected. One of these variants occurred
in a heterozygous form in 32 patients, a prevalence (9.2%) significantly higher than that in
normotensive males (2.9%, p = 0.007) and blood donors (3.0%, p = 0.001). βENaC i12-17CT was
significantly more prevalent in the hypertension group than in the two control groups combined
(4.6% vs. 1.1%, p = 0.001). When expressed in Xenopus oocytes, neither of the two ENaC amino
acid-changing variants showed a significant difference in activity compared with ENaC wild-type. No
direct evidence for a mRNA splicing defect could be obtained for the βENaC intronic variant. The
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BMC Medical Genetics 2005, 6:4 http://www.biomedcentral.com/1471-2350/6/4ratio of daily urinary potassium excretion to upright and mean (of supine and upright values) plasma
renin activity was higher in variant allele carriers than in non-carriers (p = 0.034 and p = 0.048).
Conclusions: At least 9% of Finnish patients with hypertension admitted to a specialized center
carry genetic variants of β and γENaC, a three times higher prevalence than in the normotensive
individuals or in random healthy controls. Patients with the variant alleles showed an increased
urinary potassium excretion rate in relation to their renin levels.
Background
Epidemiological studies have shown a significant correla-
tion of blood pressure levels in close relatives and higher
concordance values for occurrence of hypertension in
monozygotic vs. dizygotic twins, and thus support the
idea that genetic factors influence susceptibility to essen-
tial hypertension [1]. While recent molecular genetic stud-
ies have provided compelling evidence for mutations in at
least seven different genes underlying rare forms of mono-
genic hypertension [1,2], progress in the understanding of
the molecular basis of human essential hypertension has
been much slower. Hundreds of case-control studies have
suggested hypertension-related genetic variants of which
only a few if any have tolerated replication analyses; it is
possible that common variants of angiotensinogen [3], α-
adducin [4] and the G-protein β subunit [5] confer suscep-
tibility to elevated blood pressure in at least some popula-
tions. Since 1999, a number of genome-wide linkage
studies in families with multiple affected hypertensive
members have been published with highly varying results
(for review, see [6]). Recent large-scale searches for genes
predisposing to hypertension, published as a recent series
of articles [7-11], failed to identify definite linkage of
hypertension to any chromosomal locus, although some
DNA regions showing suggestive linkage were disclosed.
Reasons for these disappointing data were put on the
account of the unsuitability of using a single-locus linkage
strategy for a multifactorial genetic disease, inherent
genetic heterogeneity of essential hypertension, and com-
plex interplay of genetic and environmental factors under-
lying regulation of blood pressure variation [12].
Disappointments in the previous strategies justify alterna-
tive approaches in which a better phenotyping of the
study individuals is connected to their targeted molecular
genetic characterization. There are several features that
collectively make the genes encoding the beta (βENaC)
and gamma (γENaC) subunits of the kidney tubular epi-
thelial sodium channel as serious candidates for suscepti-
bility genes of low-renin human essential hypertension.
First, gain of function mutations in β and γ ENaC subunits
cause Liddle's syndrome, a well-known monogenic form
of human hypertension associated with low renin activity
and low plasma aldosterone level [13-15]. Second, com-
mon βENaC variants occur in increased frequency in
hypertensive black individuals [16-18]. Third, an exten-
sive locus-targeted study on hypertensive family members
demonstrated a significant linkage of hypertension to
chromosome 16q region harboring both the βENaC and
γENaC genes [19]. These data prompted us to carry out a
search for common variants of these two genes in Finnish
hypertensive patients who were admitted to a special
center because of treatment-resistant hypertension and
whose renin-aldosterone system was systematically exam-
ined. These circumstances provided a group of hyperten-
sive patients, in which secondary forms of hypertension
were effectively excluded and who originated from a
genetic isolate. Our data suggest that common variants of
the ENaC subunits confer susceptibility to human essen-
tial hypertension.
Methods
Patients with hypertension
The clinical records of all consecutive patients with hyper-
tension (n = 615) referred to the Hypertension Outpatient
Ward, Helsinki University Central Hospital, between
1992–96 were reviewed. Moderate-to-severe hyperten-
sion, suspicion of secondary forms of hypertension, or
hypertension resistant to drug treatment were causes to
the admittance. A letter with request to donate a blood
sample for genetic studies on hypertension was sent to
those 598 individuals whose address became available in
1998. A total of 399 individuals (67%) of these responded
and were subsequently examined at the Hypertension
Outpatient Ward in 1998 to 1999. Clinical and family his-
tories were recorded, and venous blood samples taken for
DNA analysis. Based on the previous documents and cur-
rent examinations, altogether 52 individuals were
excluded from the present study: clinical records were
missing or insufficient in four cases, 22 subjects were con-
sidered as normotensive, while 26 were judged to have a
secondary form of hypertension. The latter group con-
sisted of the following cases: renal artery stenosis (n = 12),
adrenal cortical adenoma (n = 3), hydronephrosis (n = 2),
pheochromocytoma (n = 1), IgA glomerulonephritis (n =
1), non-specific chronic glomerulonephritis (n = 1), LED
nephritis (n = 1), diabetic nephropathia (n = 1), chronic
pyelonephritis (n = 1), hypernephroma (n = 1), fibromus-
cular dysplasia (n = 1), unspecified renal failure (n = 1).
The remaining 347 patients (186 females and 161 males,
mean age 49.3 years, SD ± 10.0) comprised our final
cohort of patients with moderate-to-severe essentialPage 2 of 13
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in 283 (82%) of the patients (diuretics, 19%; beta-block-
ing agents, 35%; calcium-channel blockers, 21%; ACE-
inhibitors, 33%; angiotensin receptor antagonists, 1%).
At least two concomitant drugs were used by 24% of the
patients. A flow-chart of the study design is illustrated in
Fig. 1.
Control individuals
Blood donors
DNA was extracted from 301 randomly selected healthy
blood donors aged 40–50 years (mean, 45 years) visiting
the Finnish Red Cross Blood Transfusion Service. Their
residences represent the same capital area from which the
hypertensive patients originated.
Normotensive controls
These individuals were selected from the participants in
the Alpha-Tocopherol, Beta Carotene (ATBC) study [20]
using the criteria described previously [21]. In brief, a total
of 27271 male smokers (aged 50 to 69 years) with no pre-
vious history of myocardial infarction were initially
recruited for a cancer prevention trial. DNA samples were
available from 70% of the original participants. We
picked up all the available blood samples from those ful-
filling the following criteria: no known hypertensive dis-
order, no antihypertensive drugs ever in use, systolic and
diastolic blood pressure values ≤ 128 and ≤ 84 mmHg,
respectively, at each blood pressure measurement,
repeated five times at one-year intervals during a five-year
follow-up. We ended up with 175 normotensive men
whose mean systolic and diastolic blood pressures were
114.9 (SD ± 5.4) and 73.7 (SD ± 4.3) mmHg, respectively,
during this five-year follow-up.
The Ethics Review Committee of the Helsinki University
Central Hospital approved this study, and all patients and
controls gave their informed consent.
Laboratory measurements in the hypertensive patients
The patients were advised to stop using estrogens and
spironolactone at least 4 weeks before the tests, diuretics
and prostaglandin inhibitors at least two weeks before the
tests, and β-adrenergic antagonists and ACE inhibitors at
least one week before the test. The only antihypertensive
agents permitted at the time of the test were calcium chan-
nel blockers. Some of the patients were on oral potassium
supplementation because of hypokalemia. The mean
baseline blood pressure level at the time of captopril test
was 139 ± 16/94 ± 10 mmHg in those without any drugs
(n = 79), and 142 ± 16/95 ± 11 mmHg in those with cal-
cium channel blockers (n = 234).
Fasting blood samples were taken for determination of
serum creatinine, uric acid, cholesterol, potassium,
sodium and blood glucose concentrations. Urine samples
for determination of the daily (24 h) excretion of potas-
sium and sodium were collected. Most hypertensive
patients (n = 298) underwent a test for the responsiveness
of serum aldosterone level and plasma renin activity to
postural change. To this end, the first blood sample was
taken after at least 60 minutes of rest in supine position.
After 2 hours of standing and moderate walking, a second
blood sample was taken. This test was carried out at the
inpatient ward in 220 cases and at the outpatient ward in
78 cases. Urinary electrolyte excretion rates were analyzed
in 262 patients (26 ENaC variant carriers and 236 non-
carriers) who did not use potassium supplementation.
One to three days later, a captopril challenge test (CCT)
was carried out as described earlier [22]. This test was car-
ried out in a total of 313 patients, and was performed at
the inpatient ward in 229 cases and at the outpatient ward
in 84 cases. CCT was started by sitting for at least 30 min-
utes, followed by oral administration of 50 mg captopril.
Blood pressure in the non-dominant arm was measured at
15-minute intervals. Blood samples for the determination
of plasma renin activity and serum aldosterone
Flow diagram of the recruitment of the patients with primary hypertensionigu e 1
Flow diagram of the recruitment of the patients with primary 
hypertension.Page 3 of 13
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minutes after captopril administration.
DNA analysis
Genomic DNA was extracted from peripheral venous
blood using standard techniques. For targeted search for
ENaC variants postulated to be associated with increased
channel activity, we chose to sequence the exons 13 cod-
ing for the carboxyterminal domains of βENaC (amino
acids 515–640) and γENaC (amino acids 524–649), as
well as the 5'-flanking intronic regions, using oligonucle-
otide primers, PCR (polymerase chain reaction) condi-
tions and sequencing instruments described previously by
us [21]. DNA samples of 27 patients of those 399 initially
visiting the Hypertension Outpatient Ward showing the
lowest plasma renin activities (median 0.7 µg/L/h at 0
minutes and 0.9 at 60 minutes) and serum aldosterone
concentrations (median 236 pmol/L at 0 minutes and 212
at 60 minutes) during CCT were selected for this initial
step.
Specific PCR-based methods were set up for assaying the
three ENaC variants detected during the present study.
After PCR of the βENaC fragment, the βENaC -i12 -17CT
and βENaC G589S variants could be assayed simultane-
ously. An aliquot (8 µl) of the PCR product was digested
with 3.0 U of AluI (New England Biolabs, Beverly, Massa-
chusetts, USA), followed by analysis of the cleavage prod-
ucts on a 12% polyacrylamide gel. The wild-type (wt)
allele results in longest fragments of 266 and 137 bp,
while the variant allele produces fragments of 266 and
147 bp for βENaC -i12 -17CT, and 240 and 137 bp for
βENaC G589S. For the γENaC V546I variant, 2.0 U of
SfaNI (New England Biolabs) was used and the cleavage
products were analyzed on a 2% agarose gel. The resulting
fragment sizes were 357 and 77 bp for the wild-type allele
and 279, 78 and 77 bp for the variant allele.
For studies on the possible splicing errors brought about
by the βENaC i12-17 variant, we collected lymphocytes
from two subjects heterozygous for this variant and one
control subject. Total lymphocytic RNA was isolated using
Qiagen RNeasy kit (Qiagen, Valencia, California, USA),
and first strand synthesis was performed using Superscript
system for RT-PCR (Invitrogen Corporation, Carlsbad,
California, USA). For gene-specific PCR, we used two sets
of primers amplifying a fragment extending from exon 12,
either to exon 13 (180 bp) or 141 bp downstream of exon
13 (551 bp). The amplified products were run on a 12 %
polyacrylamide gel and visualized by ethidium bromide.
The amplified fragments were also sequenced to exclude
presence of any splicing defects. Additionally, possible
splicing differences between the wild-type and i12-17 var-
iant of βENaC were studied in silico using GrailEXP v3.3
(Perceval) exon prediction program [23].
Site-directed mutagenesis and functional characterization 
of the ENaC variants
The human βENaC cDNA and γENaC cDNA cloned into
the pBSK-SP6-globin vector were used in construction of
the βENaC G589S and γENaC V546I mutations, respec-
tively. Site-directed mutagenesis was performed using the
Transformer site-directed mutagenesis kit (Clontech Lab-
oratories, East Meadow Circle, California, USA). Muta-
genic primers used were 5'-cacaccaactttAgcttccagcctg-3'
and 5'-gctgctctgttgtctgcAtcatcgagatcatcgagg-3' for the
G589S and V546I mutations, respectively. The primer 5'-
ccctcgctcgTgtgatctggt-3', which mutates the XhoI restric-
tion enzyme site in the pBSK-SP6-globin vector, was used
as the selection primer in the mutagenesis reactions. The
mutagenic clones were sequenced to confirm the presence
of the mutations and to exclude undesired errors during
mutagenesis.
Healthy stage V and VI Xenopus oocytes were injected with
mRNAs encoding the β human (h)ENaC wild-type or
βG589S hENaC mutant, the γhENaC wt or γV546I hENaC
mutant together with the mRNA encoding the αhENaC
wt. The total amount of mRNA encoding the three αβγ
ENaC subunits was 10 ng. Electrophysiological measure-
ments were taken at 16–24 hours after injection. ENaC
activity was assessed by measurement of the amiloride-
sensitive current (INa in µA) recorded at -100 mV with a
two-electrode voltage clamp amplifier (TEV-200, Dagan
Corp.) in a standard solution containing 110 mmol/L
NaCl, 1.8 mmol/L CaCl2, 10 mmol/L HEPES-NaOH, pH
7.35. The amiloride concentration used was 5 µmol/l in
the bath solution. Four batches of oocytes were obtained
from different Xenopus frogs in which 5 to 7 oocytes were
tested for each αβγ ENaC wt and ENaC variants.
Statistical analysis
The renin and aldosterone values were nonnormally dis-
tributed, as analyzed using skewness, kurtosis and Kol-
mogorov-Smirnov tests. Therefore, nonparametric tests
(Mann-Whitney's U) were used in the statistical analyses,
and interquartile (IQ) range and median are used to
describe the distributions of target variables. When covari-
ates were included in the analyses, ANCOVA with ranks or
logarithm-transformed values of the variables was used.
Chi square test, or Fisher's exact test if observed frequency
in any cell was less than five, were used for the frequency
analysis of the variants. Logistic regression was used to
obtain age and gender adjusted odds ratios for hyperten-
sion in ENaC variant carriers vs. non-carriers. All data was
analyzed using statistical SPSS program (version 11.0).
Because of relatively small variant group sizes, the primary
analyses were performed with all variant groups com-
bined. Secondarily, the variant groups were also com-
pared separately with the wild-type ENaC group.Page 4 of 13
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Sequence analysis of the variant β and γENaC alleles. Chromatograms from both sequencing directions, nucleotide sub-
stitutions and predicted amino acid changes from three different hypertensive patients are shown.Page 5 of 13
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Identification of three common ENaC variants and 
screening for their presence in the three different study 
groups
DNA samples of 27 hypertensive patients with lowest
renin activities and aldosterone concentrations were ini-
tially selected for targeted search for ENaC variants. The
sequencing strategy chosen permits detection of muta-
tions and polymorphisms in the entire coding parts of
exons 13 of β and γENaC genes, as well as 26 or 43 nucleo-
tides at the 3'-ends of introns 12. Three different single-
nucleotide substitutions were detected, two in the βENaC
and one in the γENaC subunit (Fig. 2). Four out of the 27
samples showed a previously unreported substitution of T
for C in intron 12 of the βENaC gene (i12-17CT), located
17 nucleotides upstream of the 5'-end of exon 13. In one
DNA sample a single G to A substitution changed the
codon 589 of βENaC from GGC to AGC, predicted to
result in a substitution of serine for glycine (G589S). This
variant has been described previously [24,25]. Upon
screening of exon 13 of the γENaC gene for mutations,
one sample was detected with a novel point mutation
changing codon 546 from GTC to ATC, which results in a
substitution of isoleucine for valine (V546I).
We next conducted a search for these three ENaC variants
in our whole material of patients with essential hyperten-
sion (n = 347), normotensive males (n = 175) and ran-
domly chosen blood donors (n = 301) (Table 1).
Altogether, we identified 46 heterozygous carriers of these
variant alleles, but no homozygous or compound hetero-
zygous individuals. Their prevalence was significantly dif-
ferent in the three study groups (χ2 = 15.0, p = 0.0006).
Subanalysis of the three groups indicated that the variant
allele frequency was higher among the hypertensive
patients (9.2%) than in normotensive males (2.9%; p =
0.007) or blood donors (3.0%; p = 0.001), while in the
latter two groups it was similar (Table 1). When frequen-
cies of the individual gene variants in the hypertensive
patients were compared to those in the two other groups
(normotensive males and blood donors) combined, the
βENaC i12-17CT variant was found to occur significantly
more often among the hypertensive patients than in other
groups (p = 0.001) whereas the differences in the preva-
lences of βENaC G589S (p = 0.15) and γENaC V546I (p =
0.14) did not reach statistical significance.
Clinical characteristics of the variant allele carriers and 
non-carriers
Clinical and laboratory data of the hypertensive patients
grouped according to their carrier status of the three ENaC
variants detected are summarized in Table 2. There were
no significant differences, associated with carrying a vari-
ant allele, in the sex, age or BMI of the hypertensive
patients, nor their serum creatinine, lipid, potassium or
sodium levels. Variant alleles did not seem to associate
with cerebrovascular events or diabetes among the hyper-
tensive patients, but small numbers prevent definitive
conclusions (Table 2). Our original study protocol was
not designed to disclose health information of the two ref-
erence groups (normotensive males and healthy blood
donors), and a similar comparison of variant allele carri-
ers and non-carriers in these groups is therefore not
feasible.
Relation of the variant ENaC alleles to the activity of the 
renin-aldosterone system
The dynamics of the circulating renin and aldosterone lev-
els in most hypertensive individuals were studied during
two challenge tests: during a supine-upright postural test
and in response to captopril administration. Baseline
plasma renin activity was very similar in the patients with
and without variant alleles, whether investigated during
the postural test or captopril administration (Table 3).
Plasma renin levels after attainment of upright posture (p
= 0.11) and captopril administration (p = 0.12) were not
significantly different among carriers and non-carriers of
the ENaC variants (Table 3, Fig. 3). Plasma aldosterone
levels did not significantly vary according to the ENaC var-
iant carrier status (Table 3).
Table 1: β and γ ENaC variants identified among the three study groups
Hypertension n (%) Normotensive males n (%) Blood donors n (%) Adjusted OR (95% CI)1
All variants 32 (9.2) 5 (2.9)** 9 (3.0)** 3.1 (1.6–6.0)
βENaC i12-17CT 16 (4.6) 2 (1.1)* 3 (1.0)** 4.6 (1.6–13.0)
βENaC G589S 8 (2.3) 2 (1.1) 3 (1.0) 2.4 (0.77–7.7)
γENaC V546I 8 (2.3) 1 (0.6) 3 (1.0) 2.2 (0.63–7.5)
Non-carriers 315 (90.8) 170 (97.1) 292 (97.0)
*P<0.05 and **P<0.01 vs. Hypertension group.
1OR for hypertension (versus combined control groups) in ENaC variant carriers vs. non-carriers, adjusted for age and gender.Page 6 of 13
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minus baseline value) in the two tests according to the
ENaC variant carrier status. We found some evidence of a
blunted renin response to both postural (p = 0.21) and
captopril (p = 0.087) challenge tests in carriers of variant
alleles compared to non-carriers, but there was wide inter-
individual variation in the test results (Fig. 4). Use of cov-
ariates (urinary sodium excretion, age and BMI) did not
cause significant changes in the results of these analyses.
We next related the activity of circulating renin-aldoster-
one system to sodium-potassium homeostasis in ENaC
variant carriers and non-carriers. Serum sodium and
potassium concentrations in these two groups of hyper-
tensive patients were similar (Table 2). Urinary sodium
excretion rate was not associated with the ENaC polymor-
phisms studied (data not shown). Urinary potassium
excretion rates were not statistically significantly different
in patients with (median, 83 mmol/day) and without
Table 2: Demographic and clinical features of the hypertensive subjects, according to their ENaC variant status
Carriers of the ENaC variants Non-carriers
βENaC i12-17CT (n = 16) βENaC G589S (n = 8) γENaC V546I (n = 8) All (n = 32) (n = 315)
Female/male (n) 9/7 4/4 7/1 20/12 166/149
Age (y) 49.4 ± 8.5 49.3 ± 5.8 50.5 ± 9.0 49.7 ± 7.8 49.3 ± 10.2
BMI (kg/m2) 28.0 ± 4.9 28.2 ± 4.8 27.9 ± 3.8 28.0 ± 4.5 27.4 ± 4.9
Serum creatinine (µmol/L) 88 ± 18.9 91 ± 12.8 85 ± 17.1 88 ± 6.7 88 ± 15.1
Serum uric acid (µmol/L) 329 ± 95.3 335 ± 65.6 386 ± 173.2 338 ± 87.1 340 ± 91.2
Fasting blood glucose (mmol/L) 5.3 ± 0.9 5.7 ± 1.1 5.5 ± 0.9 5.4 ± 0.9 5.6 ± 1.1
Serum cholesterol (mmol/L) 5.5 ± 0.8 6.0 ± 1.2 5.3 ± 0.7 5.6 ± 0.9 5.6 ± 1.0
Serum potassium (mmol/L) 4.1 ± 0.3 4.2 ± 0.4 4.2 ± 0.5 4.2 ± 0.4 4.1 ± 0.3
Serum sodium (mmol/L) 141 ± 2.4 140 ± 3.5 138 ± 2.2 140 ± 2.8 140 ± 0.3
Potassium supplementation (n) 1 0 2 3 (9.4%) 31 (9.8%)
Cerebrovascular disorder (n) 1 0 0 1 (3.1%) 17 (5.4%)
Diabetes (n) 1 1 1 3 (9.4%) 36 (11.4%)
Gestational hypertension (n) 3 1 2 6 (18.8%) 44 (14.0%)
Data for age, creatinine, uric acid, glucose, cholesterol, potassium and sodium is given as mean ± SD. Carriers of the ENaC variants did not differ 
significantly from non-carriers.
Table 3: Plasma renin activity and serum aldosterone concentration during postural and captopril challenge tests
Carriers of the ENaC variants Non-carriers P-values
βENaC i12-17CT βENaC G589S γENaC V546I All All variants versus 
non-carriers
Postural test (n) 15 8 7 30 268
PRA, supine 0.7 (0.4–1.7) 0.7 (0.4–1.0) 0.6 (0.3–1.8) 0.7 (0.4–1.2) 0.8 (0.5–1.4) 0.37
PRA, upright 1.2 (0.8–2.3) 1.5 (0.7–2.9) 1.6 (0.3–2.4) 1.5 (0.7–2.4) 1.9 (1.0–3.5) 0.11
Aldosterone, supine 343 (225–398) 457 (251–592) 358 (238–622) 368 (243–482) 369 (273–474) 0.76
Aldosterone, upright 663 (353–1073) 725 (552–960) 1036 (585–1643) 761 (484–1129) 939 (584–1255) 0.21
Captopril test (n) 15 8 8 31 282
PRA, 0 min 1.2 (0.8–2.4) 1.3 (0.5–2.9) 1.3 (0.2–3.4) 1.2 (0.6–2.6) 1.4 (0.7–2.5) 0.53
PRA, 60 min 1.7 (1.0–6.2) 3.0 (0.5–5.7) 2.3 (0.5–8.2) 1.9 (0.8–5.7) 3.6 (1.3–7.7) 0.12
Aldosterone, 0min 554 (302–820) 608 (474–806) 645 (361–1312) 599 (340–845) 618 (431–877) 0.47
Aldosterone, 60min 400 (245–513) 400 (336–472) 356 (261–803) 392 (250–513) 397 (311–539) 0.41
Data is given as median (interquartile range). PRA, plasma renin activity (µg/L/h); Aldosterone, serum aldosterone concentration (pmol/L). 
Reference values: renin 0.9–2.0 (supine) and 2.0–5.0 (upright), and aldosterone 85–470 (supine) and 220–1000 (upright).Page 7 of 13
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4). However, when daily potassium excretion (dU-K, in
mmol/day) was related to plasma renin activity (in µg/L/
h), as mirrored by the renin levels during the postural
challenge test, a significant difference was noticed: the
median dU-K/renin ratios in the variant carriers vs. non-
carriers were 114 vs. 92 when supine (p = 0.29) and 56 vs.
38 when upright (p = 0.034) (Table 4); the corresponding
values for the average (mean of supine and upright) dU-
K/renin ratios were 74 and 51, respectively (p = 0.048)
(Table 4). A similar analysis of dU-K/plasma aldosterone
ratios demonstrated higher ratios in female variant carri-
ers vs. non-carriers for supine (p = 0.16), upright (p =
0.014) and the average values (p = 0.012), while no signif-
icant differences were seen in males. Collectively, these
data suggests that hypertensive individuals carrying the
ENaC variants tend to excrete increased amounts of potas-
sium in relation to prevailing plasma renin and aldoster-
one levels.
Molecular characterization of the ENaC variants
We tested whether the βG589S or γV546I have any func-
tional impact on ENaC expressed in Xenopus oocytes, the
most commonly used expression system for ENaC func-
tional studies. When αβγ ENaC subunits were co-
expressed to obtain maximal channel activity, neither the
βG589S nor γV546I affected ENaC activity as measured by
the amiloride-sensitive Na+ currents. In other words, these
data indicate that the current carried by Na+ ions through
ENaC channels present at the cell surface is similar for
ENaC wild-type and mutant channels, indicating that the
βG589S and γV546I mutations have no detectable func-
tional consequences on ENaC activity, at least when
expressed in Xenopus oocytes.
In order to clarify whether the C-T substitution at position
-17 of the intron 12 of the βENaC could affect mRNA
splicing, cDNA was synthesized from an RNA fraction
prepared from lymphocytes of two hypertensive patients
heterozygous for the βENaC i12-17CT mutation and a
control individual without this gene variant. Primer pairs
for reverse transcription were designed in a way permit-
ting identification of a possible failure to splice intron 12
properly. Regardless of the primer pairs used, similar DNA
fragments were generated from the samples of the βENaC
i12-17CT carriers and control subject (data not shown).
Furthermore, sequence analysis of the amplified DNA
fragments revealed the presence of only normally spliced
Renin values in postural test and after captopril administrationFigure 3
Renin values in postural test and after captopril administration. Individual plasma renin activities at supine, upright, 
and in response to captopril administration (CCT; 60-minute values) in carriers and non-carriers of the three ENaC variant 
alleles. The horizontal bars indicate the median renin values in each group.Page 8 of 13
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more, in silico analysis of the βENaC wild-type and variant
DNA sequences suggested no differences in exon splicing.
However, this analysis is only of predictive value and does
not exclude a splicing defect introduced by the variant
nucleotide in renal tissue.
Renin responses in postural and captopril testsFigure 4
Renin responses in postural and captopril tests. Plasma renin responses (median and interquartile ranges) during the 
postural and captopril challenge tests (stimulated values minus baseline values in both cases) in carriers and non-carriers of the 
variant ENaC alleles.
Table 4: Urinary potassium excretion and relation to plasma renin and aldosterone levels
Carriers of the ENaC variants Non-carriers P-values
βENaC i12-17CT 
(n = 14)
βENaC G589S (n 
= 7)
γENaC V546I (n = 
5)
All (n = 26) (n = 236) All variants versus 
non-carriers
dU-K (mmol) 86 (68–112) 85 (66–120) 80 (70–96) 83 (68–102) 79 (65–94) 0.23
dU-K/PRA upright 54 (31–122) 57 (38–180) 97 (43–274) 56 (35–129) 38 (23–84) 0.034
dU-K/PRA mean 67 (37–168) 77 (55–252) 107 (59–321) 74 (46–170) 51 (31–118) 0.048
dU-K/Aldo upright 0.15 (0.06–0.25) 0.10 (0.07–0.15) 0.08 (0.06–0.25) 0.10 (0.07–0.21) 0.08 (0.06–0.14) 0.108
Data is given as median (interquartile range). dU-K, daily urinary potassium excretion; PRA, plasma renin activity (µg/L/h); Aldo, serum aldosterone 
concentration (pmol/L); PRA mean, average of supine and upright PRA.Page 9 of 13
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The present study indicates that three common variants of
the kidney epithelial sodium channel ENaC occur approx-
imately three times more often in patients with moderate-
to-severe essential hypertension compared to normoten-
sive males and   While direct in vitro studies have failed to
demonstrate a gain-of-function for these ENaC variants,
their association with an increased urinary potassium loss
in relation to existing plasma renin activity suggests that
in the long run in vivo they may result in sodium
retention, suppression of renin and aldosterone levels and
hypertension.
A large number of common and rare polymorphisms of
the α-, β-and γENaC have been described in different pop-
ulations (reviewed in [26] and [27]), but their pathophys-
iologic role, if any, has remained obscure, at least in the
White populations. A systematic search in approximately
500 hypertensive probands, mostly of Caucasian origin,
disclosed seven variants of the βENaC and six variants of
the γENaC subunit, but no variant, with the possible
exception of the βENaC G589S substitution, showed an
increased ENaC activity in vitro, nor showed cosegregation
with hypertension [24,28]. The G589S variant was also
identified in a Swedish hypertensive patient [25].
Two amino acid variants, βENaC G589S and γENaC
V546I, both occurred with a frequency of about 2% in the
hypertensive patients but in only 1% of the background
population or normotensive males. The G589 is located
in the poorly conserved cytoplasmic carboxyterminal
portion of βENaC, 27 amino acids upstream of the
functionally important PY motif. Persu et al. [24] identi-
fied the same substitution in a hypertensive female with
mild hypokalemia and suppressed plasma renin activity.
Using measurements of sodium channel activity and ami-
loride-sensitive sodium flux in Xenopus oocytes, these
investigators were able to show a borderline 1.3 to 1.5-
fold increase in activity for the G589S variant compared
with the wild-type subunit. A similar trend was noticed in
our experiments (Fig. 5). It remains possible that the func-
tional expression of ENaC in Xenopus oocytes is not sensi-
tive enough to detect subtle increases in ENaC activity, as
it could well be the case for βG589S ENaC variant, and
only mutations leading to large changes in ENaC activity
are liable to be detected. On the other hand, even minute
changes in ENaC may result in significant in vivo effects
when operating for decades under the influence of unfa-
vorable living habits or variants of other modifier genes
promoting salt reabsorption. Accordingly, the βENaC
G589S could confer some susceptibility to low-renin
hypertension, but more data on untreated patients and
families are needed.
The γENaC V546I substitution is located in the second
transmembrane domain of the ENaC subunit, and it has
not been described previously. Seven out of the eight car-
riers were females, and their renin and aldosterone levels
were very similar to those in non-carriers. When expressed
in vitro in Xenopus oocytes, this substitution did not result
in an increase in sodium current (Fig. 5). It is not possible
at present to deduce whether the V546I variant constitutes
a pathophysiologically significant allele by itself or merely
a genetic marker conferring susceptibility to hypertension.
The C→T variant of the nucleotide -17 of intron 12 of
βENaC is a novel one and, interestingly, it was present in
4.6% of the hypertensive patients but in only 1% of the
301 random blood donors (p = 0.009) and 175 normo-
tensive males (p = 0.043). Patients with this variant allele
displayed the lowest plasma renin levels and responses of
all the subgroups examined (Table 3, Fig. 4), but due to
large interindividual variation the differences were not
statistically significant. This βENaC variant may have
remained undetected in earlier studies as they have mostly
Channel activity of βENaC G589S and γENaC V546I variants in vitroFigu e 5
Channel activity of βENaC G589S and γENaC V546I 
variants in vitro. Comparison of channel activity of hENaC 
wild-type, and the βhENaC G589S and γhENaC V546I vari-
ants, when expressed in Xenopus oocytes. ENaC activity was 
measured as amiloride-sensitive Na+ current. Absolute cur-
rents were 5.09 ± 0.98 and 6.75 ± 1.23 µA for ENaC wt in 
the two series of experiments (number of oocytes given in 
parentheses).Page 10 of 13
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ing this substitution. Theoretically, a mutation at this site
of an intron could affect RNA splicing. We explored this
possibility by reverse transcription-PCR experiments of
RNA samples from two variant carriers and a control indi-
vidual, prepared from peripheral lymphocytes known to
express βENaC [29]. We could not demonstrate a splicing
error, but since homozygous individuals were not availa-
ble for studies, we may have missed subtle changes. Fur-
thermore, it is not known how well βENaC mRNA
splicing in lymphocytes reflects the mechanism in kidney
epithelial cells. Another possibility is that the DNA region
around the variant nucleotide -17 of intron 12 contains
interaction site for regulatory factors affecting transcrip-
tion of βENaC in tubular cells, or the i12-17CT variant
may be in linkage disequilibrium with some yet unidenti-
fied mutation present elsewhere in the βENaC or in the
closely linked γENaC gene.
The fact that we did not find hypokalemia or statistically
significant suppression of renin levels in our patients with
variant ENaC alleles does not abandon the hypothesis
that they act as subtle genes conferring liability to sodium
retention and hypertension during lifetime. In fact, even
in cases with unequivocal Liddle's syndrome due to acti-
vating ENaC mutations the penetrance of disease pheno-
type is variable, with inconstant occurrence of
hypertension, hypokalemia and suppressed renin levels
from patient to patient [13,30-32]. This suggests that Lid-
dle's syndrome may represent an intermediate between
single-gene and complex genetic diseases, necessitating
the effect of extrinsic factors, such as substantial salt intake
or other modifier genes, to complete the spectrum of syn-
drome manifestations. It is of particular note that molec-
ular variants resulting in increased ENaC activity may
occur outside the cytoplasmic PY motif that long was con-
sidered as a critical domain to be affected in Liddle
patients [21,33,34].
Our present data are supported by findings of Rayner et al.
[18] who recently discovered another βENaC variant
(R563Q), which is located in the cytoplasmic domain just
adjacent of the cell membrane and was found to be
strongly associated with low-renin, low-aldosterone
hypertension in a South African black population. Unfor-
tunately, functional characterization of the R563Q variant
was not carried out. Previously, another βENaC variant
(T594M) was identified in the African Americans [35].
Although initially not linked to elevated blood pressure in
the Blacks [35], subsequent studies in a London black
population suggested a positive association with hyper-
tension [16,36]. The T594M substitution was reported to
result in an increased responsiveness to a cAMP analog
due to loss of protein kinase C inhibition of the ENaC
[35,37], but other studies have failed to show increased
sodium currents in transfected cells [24]. An additional
βENaC variant (G442V) present almost exclusively in
Blacks has also been suggested to be associated with bio-
chemical alterations compatible with increased ENaC
activity in vivo [17].
Our present results and the previous data summarized
above suggest that subtle β and γENaC variants do exist in
the population that may variably result in elevated ENaC
activity, suppression of plasma renin and aldosterone lev-
els, urinary loss of potassium, and elevated blood pressure
levels. Individual patients may variably manifest either
only one or several of these features, and in some of the
variant carriers these parameters may be entirely normal.
It will be of interest to test the effectiveness of amiloride
in our patients with the βG589S, i12-17CT and γV546I
variants as an antihypertensive drug as this specific ENaC
antagonist was shown to control blood pressure as well as
increase plasma renin, aldosterone and potassium levels
in black hypertensive individuals carrying the βT594M
allele [38].
There are certain limitations in our study. First, our hyper-
tensive patients represent a highly selected type of
patients, since they were recruited by admittance to a
specific center focusing on problems in conventional
treatment. The clinical study protocol was initially
designed for studies on screening for renovascular hyper-
tension in a population, which explains the use of capto-
pril test in the test panel. Unfortunately, urinary
aldosterone levels, integrating aldosterone secretion rate
over a longer observation period and serving as a valuable
marker of Liddle's syndrome [13,31], in particular when
related to urinary potassium excretion levels [30],were not
studied systematically. Our single-point plasma renin and
aldosterone measurements may have been liable to
incidental variations in their plasma levels, and prevent
direct comparison to previous studies relying on urinary
aldosterone assays. Second, our normotensive reference
population comprised of male patients only. However, we
had the advantage of picking up the extreme lowest end,
as regards systolic and diastolic blood pressure levels in
the absence of any antihypertensive drugs, from a very
large material of more than 27000 individuals [20]. Third,
due to ethical limitations of the study design, we did not
have access to the clinical data of the subjects in the two
reference groups (normotensive males and healthy blood
donors); it would have been of interest to review the
health data of ENaC variant carriers in these two groups.
Fourth, our study had limited statistical power for several
of the questions asked, particularly when either genetic
variant was analyzed alone in carriers versus non-carriers.
Therefore, for several of the questions asked in this study
these variants may well have only modest effects, too
small to be detected using the parameters of the presentPage 11 of 13
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resent an oversimplification, as it is uncertain whether
these three variants exert similar effects on the various
endpoints studied. Finally, our statistical analyses were
not corrected for multiple comparisons and therefore
some of the results observed in this study could represent
chance findings rather than real phenomena. However,
this is probably not the case for the observed increased fre-
quency of ENaC genetic variants in hypertensive patients
versus normotensive males and blood donors, because
this was the primary hypothesis tested and the p values for
these comparisons were 0.007 and 0.001, respectively.
Conclusions
We have demonstrated that almost 9% of Finnish patients
with hypertension admitted to a specialized center carry
genetic variants of β and γ subunits of the kidney
epithelial sodium channel ENaC, a percentage three times
higher than that in the normotensive individuals or ran-
dom healthy controls. Patients with the variant alleles
tended to have suppressed renin levels and renin respon-
siveness to challenging stimuli, and they showed a signif-
icantly increased urinary potassium excretion in relation
to their renin levels. It will be important to study whether
carriers of ENaC variants respond favorably to ENaC
blockers (amiloride and triamterene).
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